Identification of Cross-Protective Potential Antigens against Pathogenic Brucella spp. through Combining Pan-Genome Analysis with Reverse Vaccinology

الملخص EN

Brucellosis is a zoonotic infectious disease caused by bacteria of the genus Brucella.

Brucella melitensis, Brucella abortus, and Brucella suis are the most pathogenic species of this genus causing the majority of human and domestic animal brucellosis.

There is a need to develop a safe and potent subunit vaccine to overcome the serious drawbacks of the live attenuated Brucella vaccines.

The aim of this work was to discover antigen candidates conserved among the three pathogenic species.

In this study, we employed a reverse vaccinology strategy to compute the core proteome of 90 completed genomes: 55 B.

melitensis, 17 B.

abortus, and 18 B.

suis.

The core proteome was analyzed by a metasubcellular localization prediction pipeline to identify surface-associated proteins.

The identified proteins were thoroughly analyzed using various in silico tools to obtain the most potential protective antigens.

The number of core proteins obtained from analyzing the 90 proteomes was 1939 proteins.

The surface-associated proteins were 177.

The number of potential antigens was 87; those with adhesion score ≥ 0.5 were considered antigen with “high potential,” while those with a score of 0.4–0.5 were considered antigens with “intermediate potential.” According to a cumulative score derived from protein antigenicity, density of MHC-I and MHC-II epitopes, MHC allele coverage, and B-cell epitope density scores, a final list of 34 potential antigens was obtained.

Remarkably, most of the 34 proteins are associated with bacterial adhesion, invasion, evasion, and adaptation to the hostile intracellular environment of macrophages which is adjusted to deprive Brucella of required nutrients.

Our results provide a manageable list of potential protective antigens for developing a potent vaccine against brucellosis.

Moreover, our elaborated analysis can provide further insights into novel Brucella virulence factors.

Our next step is to test some of these antigens using an appropriate antigen delivery system.